Yüklüyor......
A review of the pharmacology and clinical efficacy of brivaracetam
Brivaracetam (BRV; Briviact) is a new antiepileptic drug (AED) approved for adjunctive treatment of focal (partial-onset) seizures in adults. BRV is a selective, high-affinity ligand for synaptic vesicle 2A (SV2A) with 15- to 30-fold higher affinity than levetiracetam, the first AED acting on SV2A....
Kaydedildi:
| Yayımlandı: | Clin Pharmacol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5783144/ https://ncbi.nlm.nih.gov/pubmed/29403319 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S114072 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|